Literature DB >> 26953940

Efficacy of a Recombinant Turkey Herpesvirus H5 Vaccine Against Challenge With H5N1 Clades 1.1.2 and 2.3.2.1 Highly Pathogenic Avian Influenza Viruses in Domestic Ducks (Anas platyrhynchos domesticus).

Mary J Pantin-Jackwood1, Darrell R Kapczynski1, Eric DeJesus1, Mar Costa-Hurtado1, Gwenaelle Dauphin2, Astrid Tripodi2, John R Dunn3, David E Swayne1.   

Abstract

Domestic ducks are the second most abundant poultry species in many Asian countries and have played a critical role in the epizootiology of H5N1 highly pathogenic avian influenza (HPAI).In this study, the protective efficacy of a live recombinant vector vaccine based on a turkey herpesvirus (HVT) expressing the H5 gene from a clade 2.2 H5N1 HPAI strain (A/Swan/Hungary/4999/ 2006) (rHVT-H5/2.2), given at 3 days of age, was examined in Pekin ducks (Anas platyrhynchos domesticus). The vaccine was given alone or in combination with an inactivated H5N1 clade 2.3.2.1 reverse genetic (rgGD/2.3.2.1) vaccine given at 16 days of age, either as a single vaccination or in a prime-boost regime. At 30 days of age, ducks were challenged with one of two H5N1 HPAI viruses: A/duck/Vietnam/NCVD-2721/2013 (clade 1.1.2) or A/duck/Vietnam/NCVD-1584/2012 (clade 2.3.2.1.C). These viruses produced 100% mortality in less than 5 days in nonvaccinated control ducks. Ducks vaccinated with the rgGD/2.3.2.1 vaccine, with or without the rHVT-H5/2.2 vaccine, were 90%-100% protected against mortality after challenge with either of the two H5N1 HPAI viruses. The rHVT-H5/2.2 vaccine alone, however, conferred only 30% protection against mortality after challenge with either H5N1 HPAI virus; the surviving ducks from these groups shed higher amount of virus and for longer than the single-vaccinated rgGD/2.3.2.1 group. Despite low protection, ducks vaccinated with the rHVT-H5/2.2 vaccine and challenged with the clade 1.1.2 Vietnam virus had a longer mean death time than nonvaccinated controls (P = 0.02). A booster effect was found on reduction of virus shedding when using both vaccines, with lower oropharyngeal viral titers at 4 days after challenge with either HPAI virus (P < 0.05). Neither rHVT-H5/2.2 nor standard HVT vaccine could be detected in samples collected from multiple tissues at different time points, indicting minimal levels of viral replication. In conclusion, although a minor effect on survival was observed, this study demonstrates the suboptimal protection with the rHVT-H5/2.2 vaccine given alone in Pekin ducks against H5N1 HPAI viruses and only a minor additive effect on virus shedding reduction when used with an inactivated vaccine in a prime-boost regime.

Entities:  

Keywords:  ducks; highly pathogenic avian influenza; turkey herpesvirus-H5 vaccine; vaccination; vaccines

Mesh:

Substances:

Year:  2016        PMID: 26953940     DOI: 10.1637/11282-091615-Reg.1

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  4 in total

Review 1.  Recent outbreaks of highly pathogenic avian influenza viruses in South Korea.

Authors:  Hye Kwon Kim; Dae Gwin Jeong; Sun-Woo Yoon
Journal:  Clin Exp Vaccine Res       Date:  2017-07-26

2.  Application of HDR-CRISPR/Cas9 and Erythrocyte Binding for Rapid Generation of Recombinant Turkey Herpesvirus-Vectored Avian Influenza Virus Vaccines.

Authors:  Pengxiang Chang; Faisal Ameen; Joshua E Sealy; Jean-Remy Sadeyen; Sushant Bhat; Yongqing Li; Munir Iqbal
Journal:  Vaccines (Basel)       Date:  2019-11-22

3.  Distinct polymorphisms in a single herpesvirus gene are capable of enhancing virulence and mediating vaccinal resistance.

Authors:  Andelé M Conradie; Luca D Bertzbach; Jakob Trimpert; Joseph N Patria; Shiro Murata; Mark S Parcells; Benedikt B Kaufer
Journal:  PLoS Pathog       Date:  2020-12-11       Impact factor: 6.823

Review 4.  Advances in Development and Application of Influenza Vaccines.

Authors:  Jidang Chen; Jiehuang Wang; Jipei Zhang; Hinh Ly
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.